Skip to main content

Osimertinib dimesylate (C007B-382049)

Catalog No.
C007B-382049
Mfr. No.
O650598-100mg
Mfr. Name
Aladdin Scientific
Qty/UOM
1
UOM
EA
Price: $184.42
List Price: $204.92

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Adding to cart… The item has been added
Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC 50 s of 12 and 1 nM against EGFR L858R and EGFR L858R/T790M , respectively.In VitroOsimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor (TKIs) in inhibiting EGFR phosphorylation in EGFR cells harboring sensitising EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del), with mean IC 50 values ranging from 13 to 54 nM for Osimertinib (AZD-9291). Osimertinib (AZD-9291) also potently inhibits phosphorylation of EGFR in T790M mutant cell lines (H1975 (L858R/T790M), PC-9VanR (ex19del/T790M), with mean IC 50 potency less than 15 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoThe tumor-bearing mice are treated with Osimertinib (AZD-9291) (5 mg/kg/day) for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice displays nearly 80% reduction in tumor volume by magnetic resonance imaging MRI after therapy with Osimertinib (AZD-9291), while 5 of 5 mice treated with vehicle shows tumor growth . Osimertinib (AZD-9291) demonstrates improved rat PK, reduced hERG affinity, and improved IGF1R margins relative to the previously described compounds, and so this compound is selected for further investigation. Osimertinib (AZD-9291) also offers an additional degree of broader chemical and profile diversity when compared to the previously described lead compounds. Upon dosing Osimertinib (AZD-9291) in three efficacy models, The comparable efficacy is observed at relatively low doses (10 mg/kg per day). The excellent efficacy is also observed when Osimertinib (AZD-9291) is dosed at 5 mg/kg per day. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:EGFR L858R 12 nM (IC 50 ) EGFR L858R/T790M 1 nM (IC 50 ). Specification: 0.98 Molecular Formula: C30H41N7O8S2 Molecular Weight: 691.82 PubChem CID: 92044416 Isomeric SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O.CS(=O)(=O)O
UPC:
51111872
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
O650598-100mg
CAS:
2070014-82-1
Product Size:
100mg

Cenmed Satisfaction Guarantee
Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

Testimonial
"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR

Testimonial
"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER

Testimonial
"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN

Testimonial
"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.